Latest news with #Varipulse
Time of India
24-07-2025
- Business
- Time of India
Boston Scientific lifts annual profit forecast, sees smaller tariff impact
Bengaluru: Boston Scientific raised its annual profit forecast on Wednesday, banking on strong demand for its heart devices , and trimmed its expectation for tariff-related costs to half of the previously projected amount. Shares of the company rose 4.8% in morning trading following the results. "Based on the current schedule of expected tariffs, we now anticipate a full-year headwind of about $100 million, down from a $200 million estimate," CFO John Monson said during a call with analysts. The company expects to offset the remaining tariff impact through strong sales performance, favorable product mix and spending control, Monson added. A rise in surgical procedures has boosted sales for medical device makers such as Boston Scientific, helping counter broader concerns about healthcare spending. Executives credited strong trial results and expanded product indications for fueling physician adoption of key cardiovascular devices such as Watchman and Farapulse, the firm's main growth drivers that saw steady quarterly demand. The company said the proposed rules by the Centers for Medicare & Medicaid Services regarding certain cardiac procedures would further benefit its technologies. Farapulse, which is approved in the U.S. for some patients with intermittent atrial fibrillation, competes with Johnson & Johnson's Varipulse and Medtronic's PulseSelect in the pulsed field ablation (PFA) market. Rival Johnson & Johnson last week posted strong medtech sales, aided by its heart devices, Varipulse and Trupulse. JP Morgan analyst Robbie Marcus said the profit forecast raise was larger than many had expected, especially given Boston Scientific is now moving past the initial U.S. rollout of Farapulse. "That said, the outlook still appears conservative to us," Marcus added. Boston Scientific now expects 2025 adjusted profit of $2.95 to $2.99 per share, up from its prior view of $2.87 to $2.94.
Reuters
23-07-2025
- Business
- Reuters
Boston Scientific lifts annual profit forecast, sees smaller tariff impact
July 23 (Reuters) - Boston Scientific (BSX.N), opens new tab raised its annual profit forecast on Wednesday, banking on strong demand for its heart devices, and trimmed its expectation for tariff-related costs to half of the previously projected amount. Shares of the company rose 4.8% in morning trading following the results. "Based on the current schedule of expected tariffs, we now anticipate a full-year headwind of about $100 million, down from a $200 million estimate," CFO John Monson said during a call with analysts. The company expects to offset the remaining tariff impact through strong sales performance, favorable product mix and spending control, Monson added. A rise in surgical procedures has boosted sales for medical device makers such as Boston Scientific, helping counter broader concerns about healthcare spending. Executives credited strong trial results and expanded product indications for fueling physician adoption of key cardiovascular devices such as Watchman and Farapulse, the firm's main growth drivers that saw steady quarterly demand. The company said the proposed rules by the Centers for Medicare & Medicaid Services regarding certain cardiac procedures would further benefit its technologies. Farapulse, which is approved in the U.S. for some patients with intermittent atrial fibrillation, competes with Johnson & Johnson's (JNJ.N), opens new tab Varipulse and Medtronic's (MDT.N), opens new tab PulseSelect in the pulsed field ablation (PFA) market. Rival Johnson & Johnson last week posted strong medtech sales, aided by its heart devices, Varipulse and Trupulse. JP Morgan analyst Robbie Marcus said the profit forecast raise was larger than many had expected, especially given Boston Scientific is now moving past the initial U.S. rollout of Farapulse. "That said, the outlook still appears conservative to us," Marcus added. Boston Scientific now expects 2025 adjusted profit of $2.95 to $2.99 per share, up from its prior view of $2.87 to $2.94. It posted adjusted profit of 75 cents per share for the second quarter, topping analysts' average estimate of 72 cents, according to LSEG.
Irish Examiner
23-07-2025
- Business
- Irish Examiner
Heart device sales help Boston Scientific beat profit estimates
Biomedical firm Boston Scientific has raised its annual profit forecast after strong demand for its heart devices helped the US medical device maker beat second-quarter profit estimates. Shares of the Massachusetts-based company rose by over 3% in pre-market trading following the results. A rise in surgical procedures has benefited medical device manufacturers such as Boston Scientific, as it boosted sales and helped offset broader concerns about healthcare spending pressures. Analysts said hospital utilization trends were robust during the second quarter, with hospital checks pointing to high single-digit volume growth - well above the historical average. Boston Scientific's main growth drivers, Farapulse and Watchman, which use short high-voltage pulses to treat certain abnormal heart rhythm conditions, saw strong demand during the quarter. Farapulse, approved in the US to treat certain patients with intermittent atrial fibrillation, competes with Johnson & Johnson's Varipulse and Medtronic's PulseSelect in the market for pulsed field ablation systems. Rival Johnson & Johnson last week posted strong medtech sales, aided by its heart devices, Varipulse and Trupulse. The company reported net sales of $5.06bn (€4.33bn) during the second quarter beating estimates of $4.9bn. The majority of these sales, $3.2bn, were in the US with Europe, the Middle East, and Africa accounting for just $878m. The company's cardiovascular unit reported quarterly sales of $3.34bn, surpassing estimates of $3.20bn. 'Excellent quarter' Chairman and chief executive of Boston Scientific, Mike Mahoney, said it was another 'excellent quarter' for the company 'marked by exceptional top-line performance' which delivered 'margin expansion and prioritized investment for future growth'. Boston Scientific expects 2025 adjusted profit of $2.95 to $2.99 per share, up from the prior view of $2.87 to $2.94 earlier. It posted an adjusted profit of 75c per share for the second quarter, topping analysts' average estimate of 72 cents, according to data compiled by LSEG. Boston Scientific began operating in Ireland in 1994. It has a large campus in Cork as well as several other locations across the island. According to its company's Irish operations' most recent financial documents, it employed 6,405 during 2023. Reuters
Yahoo
25-06-2025
- Business
- Yahoo
Oppenheimer Sees Strong Upside for Abbott (ABT) with Volt System and Diabetes Innovation
Abbott Laboratories (NYSE:ABT) ranks among the top stocks for an early retirement portfolio. On June 18, Oppenheimer reaffirmed its $140 price target and Outperform rating on Abbott Laboratories (NYSE:ABT), noting growing confidence in the company's Volt system and future glucose-ketone monitoring technology. Following the observation of live PFA (pulsed field ablation) case viewings of rival systems, such as Varipulse/CARTO and Farapulse/Opal, the research firm voiced increasing optimism concerning Volt. Varipulse's uptake has been 'subdued' despite price parity with Farapulse, according to Oppenheimer. Oppenheimer found two significant catalysts for Abbott Laboratories (NYSE:ABT) that might boost the company's performance in the second half of 2025. First, if Abbott leverages cost as a competitive advantage, the possible approval of Volt PMA might result in 'significant gains' in electrophysiology. The second driver is Abbott's glucose-ketone dual sensor system, which was recently revealed to be integrated with the insulin pump from Tandem Diabetes Care. Abbott Laboratories (NYSE:ABT) is a leading global healthcare company that manufactures a wide range of branded generic medications, medical devices, diagnostics, and nutritional items. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None.
Yahoo
25-06-2025
- Business
- Yahoo
Oppenheimer Sees Strong Upside for Abbott (ABT) with Volt System and Diabetes Innovation
Abbott Laboratories (NYSE:ABT) ranks among the top stocks for an early retirement portfolio. On June 18, Oppenheimer reaffirmed its $140 price target and Outperform rating on Abbott Laboratories (NYSE:ABT), noting growing confidence in the company's Volt system and future glucose-ketone monitoring technology. Following the observation of live PFA (pulsed field ablation) case viewings of rival systems, such as Varipulse/CARTO and Farapulse/Opal, the research firm voiced increasing optimism concerning Volt. Varipulse's uptake has been 'subdued' despite price parity with Farapulse, according to Oppenheimer. Oppenheimer found two significant catalysts for Abbott Laboratories (NYSE:ABT) that might boost the company's performance in the second half of 2025. First, if Abbott leverages cost as a competitive advantage, the possible approval of Volt PMA might result in 'significant gains' in electrophysiology. The second driver is Abbott's glucose-ketone dual sensor system, which was recently revealed to be integrated with the insulin pump from Tandem Diabetes Care. Abbott Laboratories (NYSE:ABT) is a leading global healthcare company that manufactures a wide range of branded generic medications, medical devices, diagnostics, and nutritional items. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
